on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Announces Positive Start to 2026
Berlin-based Eckert & Ziegler SE has reported a 7% increase in sales for the first quarter of 2026, reaching €72.9 million compared to €68.2 million during the same period last year. Despite the growth, the Group's EBIT saw a slight decline of 2%, totalling €16.0 million, attributed to a weaker product mix in the Isotope Products segment. Meanwhile, net income rose by 7% to €10.4 million.
The Medical segment performed notably well, generating €41.5 million in sales, contrasting with €34.4 million in the previous year. Particularly strong was the pharmaceutical radioisotope business. Conversely, the Isotope Products segment saw a sales drop of approximately 7%.
Eckert & Ziegler has confirmed its 2026 forecast, maintaining expectations of €320 million in sales and €80 million in adjusted EBIT.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news